What is Zone7?
Founded in 2017, Zone7 operates a proprietary AI platform designed to synthesize disparate datasets into actionable insights. The company serves a diverse clientele by detecting complex patterns that human analysts might overlook, providing proactive recommendations that mitigate physical risk and enhance operational functionality. With a global footprint spanning Palo Alto, Tel Aviv, and London, Zone7 is uniquely positioned to scale its predictive modeling capabilities across professional sports organizations and high-performance enterprise environments. The company's core value proposition lies in its ability to transform raw data into a strategic asset for longevity and peak output.
How much funding has Zone7 raised?
Zone7 has raised a total of $10.5M across 2 funding rounds:
Angel/Seed
$2.5M
Series A
$8M
Angel/Seed (2019): $2.5M with participation from Resolute Ventures
Series A (2021): $8M led by Joyance Partners, UpWest, Blumberg Capital, PLG Ventures, and Resolute Ventures
Key Investors in Zone7
Resolute Ventures
Resolute Ventures supports founders at the beginning of their entrepreneurial journey by leading pre-seed and seed funding rounds, emphasizing community, mentorship, and team-building.
Joyance Partners
A venture capital firm focused on investing in startups that create delightful, healthy, and high-functioning experiences for their users.
UpWest
A cross-border venture capital firm that bridges the gap between Israeli entrepreneurs and the US market, providing strategic guidance and capital to early-stage startups.
What's next for Zone7?
With this major enterprise-level funding, Zone7 is poised to accelerate its product development roadmap and expand its market reach. The capital infusion will likely be directed toward enhancing the platform's predictive accuracy and integrating deeper analytical capabilities to support broader health and wellness applications. As the firm transitions from its initial scaling phase into a more mature market presence, the focus will shift toward solidifying its competitive moat through proprietary algorithm refinement and strategic partnerships. Investors are betting on the company's ability to redefine the standard for proactive health management in high-stakes environments, setting the stage for potential future expansion into adjacent sectors such as corporate wellness and industrial safety.
See full Zone7 company page
